Our client:

Auris Medical (NASDAQ: EARS) is a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology and central nervous system disorders


The challenge:

Auris had IPO’d but when the market cap moved rapidly in the wrong direction, the Board had resolved, confidentially,  to replace the incumbent with a CFO who would properly represent the company’s value proposition to both US and mainland-EU investors

How our approach made a difference:

A full search was completed in under six weeks from briefing to offer. Auris Medical’s share price stabilised and the stock now holds buy signals from both short and long-term moving averages, with a positive forecast for the stock

Share this: